Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy al...
Saved in:
| Main Authors: | Marco Donia, Rikke Andersen, Troels Holz Borch, Özcan Met, Eva Ellebaek, Inge Marie Svane |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000668.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
by: Rikke Andersen, et al.
Published: (2025-02-01) -
Biomarkers for response to TIL therapy: a comprehensive review
by: Marco Donia, et al.
Published: (2024-03-01) -
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
by: Mario Sznol, et al.
Published: (2020-05-01) -
18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma
by: Tine Gadegaard Hindso, et al.
Published: (2025-02-01) -
Clinical response to immune checkpoint inhibitors in immunocompromised patient with metastatic non-melanoma skin cancer
by: P. Díaz Morales, et al.
Published: (2024-01-01)